ESHG

ESHG: UK Study Finds 6 Percent of Renal Cell Carcinoma Patients Carry Cancer Risk Variant

Researchers looked for pathogenic or likely pathogenic variants in 121 cancer risk genes in whole-genome sequencing data from 1,336 unselected RCC patients.

Diversity Problem Hinders Adoption of Polygenic Risk Scores, According to ESHG Panel

Polygenic risk scores have the potential to impact cancer screening, autoimmune disease testing, and therapeutics development, but more diverse data is needed.

ESHG

ESHG: UK Study Finds 6 Percent of Renal Cell Carcinoma Patients Carry Cancer Risk Variant

Diversity Problem Hinders Adoption of Polygenic Risk Scores, According to ESHG Panel

Kazia to Raise $2M in Registered Direct Offering

Neurogene Doses First Two Rett Syndrome Patients in Gene Therapy Trial

280Bio Begins Phase I Trial in Patients With Solid Tumors Harboring KRAS, NRAS, HRAS Mutations

In Brief This Week: Sernova, Akeso, RoslinCT, GeNeuro, Effector Therapeutics, ARUP Laboratories

Gilead Lays off 7 Percent of Cell Therapy Staff to 'Optimize Operational Efficiency'

Erasca to Begin Pivotal Phase III Study of Naporafenib in NRAS-Mutant Melanoma Next Year